Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
CytomX Therapeutics to Present at Upcoming Healthcare Conferences

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY(R) in Patients with Relapsed or Refractory Melanoma

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics to Announce Third Quarter 2019 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Announces New Employment Inducement Grants

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer

-Industry Veteran Joins to Advance Maturing Platform and Pipeline to Next Phase of Development-

CTMX : 5.37 (-0.19%)
CytomX Therapeutics to Present at Upcoming Healthcare Conferences

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
Cytomx Therapeut Set to Possibly Rebound After Yesterday's Selloff of 2.49%

Cytomx Therapeut (NASDAQ:CTMX) traded in a range yesterday that spanned from a low of $8.52 to a high of $8.90. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $8.78...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTMX : 5.37 (-0.19%)
CytomX Therapeutics to Announce Second Quarter 2019 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
Cytomx Therapeut has the Best Relative Performance in the Biotechnology Industry (CTMX , HRTX , FGEN , SGEN , LJPC )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CTMX : 5.37 (-0.19%)
FGEN : 36.98 (+5.72%)
HRTX : 21.52 (+3.26%)
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
Cytomx Therapeut Shares Down 20.3% Since SmarTrend's Sell Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on February 27th, 2019 at $12.97. In approximately 4 months, Cytomx Therapeut has returned 20.32% as of today's recent price of $10.33....

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting

- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types -

CTMX : 5.37 (-0.19%)
CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting

CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.37 (-0.19%)
Relatively Good Performance Detected in Shares of Cytokinetics Inc in the Biotechnology Industry (CYTK , CTMX , FLXN , CHRS , SGMO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CYTK : 8.16 (+0.62%)
CTMX : 5.37 (-0.19%)
FLXN : 16.10 (+0.75%)
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 5.37 (-0.19%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.89 , AIZ -0.19 , SBAC +2.45 , SO -0.27 , WELL +0.30
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar